

Amendments to the Specification:

On page 1, above the Title, insert the following new heading:

TITLE OF THE INVENTION

On page 1, line 5, delete the Title and insert the following new title:

**CIS-9, TRANS-11 ISOMER OF CONJUGATED LINOLEIC ACID (CLA) FOR TREATING
INFLAMMATORY DISEASES**

On page 1, after the Title insert the following new heading and section:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a 35 U.S.C. § 371 filing of PCT application PCT/EP2003/014592, filed December 19, 2003, which claims priority from German Application No. 103 32 712.6, filed on July 18, 2003, the entire specifications of which are incorporated by reference herein.

On page 1, delete the text on lines 8-15, and insert the following new heading, section and heading:

FIELD OF THE INVENTION

The application relates generally to pharmaceuticals for treating inflammatory diseases, and more particularly to medicaments for treating inflammatory diseases, for example, respiratory diseases including asthma.

BACKGROUND INFORMATION

On page 3, line 10, insert the following new headings and sections:

SUMMARY OF THE INVENTION

Briefly described, in one aspect of the invention, a medicament comprising the cis-9, trans-11 isomer of conjugated linoleic acid for treating inflammatory diseases is provided. The medicament may act against the hypersensitivity of the bronchia. The inflammatory disease may

be a respiratory disease, including a rheumatic disease. The rheumatic disease may include asthma.

In another aspect of the invention, a method for inhibiting the proliferation of human or animal cells of the immune systems involved in an immune response includes administering the cis-9, trans-11 isomer of conjugated linoleic acid to a patient in need thereof. A technical grade of the cis-9, trans-11 isomer of conjugated linoleic acid may be administered, and which includes an amount of at least 30% by weight based on the total weight of the conjugated linoleic acid. The acyl moiety of the technical grade cis-9, trans-11 isomer of conjugated linoleic acid includes at most 30% by weight of trans-10,cis-12 isomers, and in total less than 1% by weight of 8,10-11,13 and *trans,trans* isomers based on the total content of conjugated linoleic acid. The cis-9, trans-11 isomer of conjugated linoleic acid may be administered sub-cutaneously, intramuscularly, per inhalation, *per infusionem*, topically or orally to a patient in need thereof, and may also be incorporated into a pharmaceutically acceptable carrier

In another aspect of the invention, a composition for the treatment of asthma includes the cis-9, trans-11 isomer of conjugated linoleic acid.

In yet another aspect of the invention, a nutritional, functional food, or dietary supplement includes the cis-9, trans-11 isomer of conjugated linoleic acid, and may be administered in amounts of from 0.05 to 5 grams per day.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURES 1A and 1B illustrate the modulation of LPS/serum-stimulated BEAS-2B by cis-9, trans-11 CLA and LA;

FIGURES 2A and 2B illustrate the effects of cis-9, trans-11 CLA and LA on the production of IL-8 and IL-6 by stimulated BEAS-2B after twenty-four hours; and

FIGURE 3 illustrates the expression of IL-8 and IL-6 in LPS and serum-stimulated BEAS-2B over a four hour and twelve hour periods of treatment.

On page 3, after the heading “Detailed description of the invention” delete the text on lines 14-16, and replace with the following new paragraph:

According to an aspect of the invention, the cis-9, trans-11 isomer of conjugated linoleic acid for the production of a medicament for treating inflammatory diseases and for a nutritional, functional food or dietary supplemental agent is provided.

On page 6, after the heading “EXAMPLES” insert the following new paragraph:

The invention is further illustrated by the following examples, which are not intended to limit the scope thereof.

On page 11, after the heading “Claims” insert the following new statement:

What is claimed is:

On page 13, delete lines 1-5 (the heading “Summary” and paragraph) and insert the following new heading and section:

ABSTRACT OF THE DISCLOSURE

A composition and medicament comprising the cis-9, trans-11 isomer of conjugated linoleic acid for treating inflammatory diseases, including asthma, is provided. A method for inhibiting the proliferation of human or animal cells of the immune systems involved in an immune response including administering the cis-9, trans-11 isomer of conjugated linoleic acid to a patient is also provided. A nutritional, functional food, or dietary supplement including the cis-9, trans-11 isomer of conjugated linoleic acid is also provided.